Free Delivery Over $100
|
|
|||
|
||||
OverviewFull Product DetailsAuthor: Henning Willers , Iris EkePublisher: Springer Nature Switzerland AG Imprint: Springer Nature Switzerland AG Edition: 1st ed. 2020 Weight: 0.575kg ISBN: 9783030497033ISBN 10: 3030497038 Pages: 364 Publication Date: 12 August 2021 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of ContentsIntroduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges.- Translating Targeted Radiosensitizers into the Clinic.- Cartography of the Radiogenome of Human Cancers.- Mechanisms and Markers of Clinical Radioresistance.- Preclinical Strategies for Testing of Targeted Radiosensitizers.- 3D Radiation Biology for Identifying Radiosensitizers.- Preclinical in vivo evaluation of novel radiosensitizers by local tumor control experiments.- Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers.- Targeting the DNA Damage Response for Radiosensitization.- Targeting Tumor Metabolism to Overcome Radioresistance.-Targeting Tumor Hypoxia.- Normalizing the Tumor Microenvironment for Radiosensitization.- Radiosensitizers in the Era of Immuno-Oncology.- Index.ReviewsAuthor InformationHenning Willers, M.D., is an Associate Professor of Radiation Oncology at Harvard Medical School and an Associate Radiation Oncologist in the Department of Radiation Oncology at Massachusetts General Hospital. He is also the Director of the Thoracic Radiation Oncology Program at Massachusetts General Hospital. As a clinician-scientist, Dr. Willers’ clinical efforts have focused on improving treatment outcomes for patients with lung cancer. His basic and translational research activities are directed at elucidating how lung cancers respond to radiation and radiosensitizing drugs, and specifically seeking to identify the signaling pathways that contribute to the radioresistance of KRAS-mutant lung adenocarcinoma. Dr. Willers’ lab also studies the DNA repair pathways that are increasingly recognized to be altered in lung cancer and other cancer types. The goal of these studies is to establish genomic as well as functional protein biomarkers that will allow clinicians to identify patients whose tumors will exhibit increased sensitivity to specific DNA damaging treatments, including proton beam radiation and PARP inhibitors. Iris Eke is currently a researcher at Stanford University. She earned her M.D. at the Technical University Munich, Germany. During her Ph.D. in Experimental Radiation Oncology at the Technical University Dresden, Germany, she focused on the innovative concept to target cell-extracellular matrix interactions to overcome radio- and chemoresistance and elucidated several new mechanistic insights. At the National Cancer Institute, National Institute of Health, Dr. Eke studied the mechanisms of tumor adaptation after multifractionated radiotherapy with the goal to identify novel potential drug therapy targets involving radiation-induced target activation and DNA repair. Tab Content 6Author Website:Countries AvailableAll regions |
||||
